Irish Pharmaceutical Healthcare Association

Politician(s) lobbied: Barry Andrews (MEP), European Parliament; Cynthia Ní Mhurchú (MEP), European Parliament; Michael McNamara (MEP), European Parliament; Nina Carberry (MEP), European Parliament; Regina Doherty (MEP), European Parliament; Maria Walsh (MEP), European Parliament; Seán Kelly (MEP), European Parliament; Aodhán Ó Ríordáin (MEP), European Parliament

Intent: Request a vote in the European Parliament in favour of a resolution to pause the implementation timetable of the UWWTD.

Methods: Letter

Politician(s) lobbied: Niall Redmond (Assistant Secretary), Department of Health

Intent: Finalisation of Agreement in advance of IPHA Conference.

Methods: Informal communication

Politician(s) lobbied: Muiris O’Connor (Assistant Secretary), Department of Health

Intent: Timing of requirement after enactment of new legislation should be longer to give industry better opportunity to organise.

Methods: EmailLetter

Politician(s) lobbied: John Newham (Assistant Secretary), Department of Enterprise, Trade and Employment; Muiris O’Connor (Assistant Secretary), Department of Health

Intent: Highlight IPHA's position on a National Life Sciences Strategy to cross departmental representatives.

Methods: Meeting

Politician(s) lobbied: Jennifer Carroll MacNeill (Minister), Department of Health; Colm Burke (TD), Dáil Éireann, the Oireachtas; Michael Cahill (TD), Dáil Éireann, the Oireachtas; Sorca Clarke (TD), Dáil Éireann, the Oireachtas; David Cullinane (TD), Dáil Éireann, the Oireachtas; Martin Daly (TD), Dáil Éireann, the Oireachtas; Pádraig Rice (TD), Dáil Éireann, the Oireachtas; Peter Roche (TD), Dáil Éireann, the Oireachtas; Pádraig O'Sullivan (TD), Dáil Éireann, the Oireachtas; Marie Sherlock (TD), Dáil Éireann, the Oireachtas; Teresa Costello (Senator), Seanad; Manus Boyle (Senator), Seanad; Maria Byrne (Senator), Seanad; Maria Byrne (Senator), Seanad; Tom Clonan (Senator), Seanad; Colm Henry (Chief Clinical Officer), Health Service Executive; Nicole Ryan (Senator), Seanad

Intent: Meeting to discuss the impact this reclassification would have on the wider healthcare system and sharing the findings of a socio-economic analysis completed by IPHA>

Methods: EmailMeeting

Politician(s) lobbied: Muiris O’Connor (Assistant Secretary), Department of Health

Intent: (i) Support for IPHA EU Presidency planned events and priorities. (ii) Highlighting industry position on EU legislative files - Critical Medicines Act and BioTech Act. (iii) Raise concerns relating to the impact of UWWTD on supply of medicines and also the impact of moving OTC AMR medicines to presccription only. (iv) Support for a biopharma policy forum to coincide with European Commissions visit to Ireland in July.

Methods: MeetingPhone call

Politician(s) lobbied: John Newham (Assistant Secretary), Department of Enterprise, Trade and Employment; Peter Burke (Minister), Department of Enterprise, Trade and Employment

Intent: (1) To provide the industry perspective on a holistic Life Sciences Strategy for Ireland, which encompasses a bench to bedside philosophy (2) An ask to publish the Life Science Strategy to coincide with Ireland holding the EU Presidency.

Methods: EmailMeetingSubmission

Politician(s) lobbied: Colm Henry (Chief Clinical Officer), Health Service Executive

Intent: Meeting to explore how IPHA could support the HSE in strengthening public understanding of self-care and sharing research into same.

Methods: Email

Politician(s) lobbied: David Cullinane (TD), Dáil Éireann, the Oireachtas; Marie Sherlock (TD), Dáil Éireann, the Oireachtas; Stephen Foley (Special Adviser), Department of Enterprise, Trade and Employment; Colm Burke (TD), Dáil Éireann, the Oireachtas; Pádraig O'Sullivan (TD), Dáil Éireann, the Oireachtas

Intent: Discuss the impact of reclassification would have on the wider healthcare system.

Methods: EmailPhone callVirtual Meeting

Politician(s) lobbied: Shane Moynihan (TD), Dáil Éireann, the Oireachtas; Joe Neville (TD), Dáil Éireann, the Oireachtas

Intent: To provide an understanding of the challenges facing the pharmaceutical industry including delayed access to medicines.

Methods: Meeting